Côd QR

Immune checkpoint inhibitors in pancreatic adenocarcinoma: a systematic review and meta analysis of clinical outcomes

BackgroundPancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies, with poor outcomes despite therapeutic advancements. Immune checkpoint inhibitors (ICIs) have transformed cancer care, but their efficacy in PDAC is limited due to the tumor’s immunosuppressive microen...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: Aisha Al-Khinji, Noora Al-Korbi, Sheikha Al-Kuwari, Abdullatif Al-Hor, Dhafer Malouche
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Frontiers Media S.A. 2025-08-01
Cyfres:Frontiers in Oncology
Pynciau:
pancreatic ductal adenocarcinoma (PDAC)
immune checkpoint inhibitors (ICIs)
tumor mutational burden
combination therapy
survival outcomes
Mynediad Ar-lein:https://www.frontiersin.org/articles/10.3389/fonc.2025.1569884/full
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg